Mouse models of experimental atherosclerosis.

In situ imaging of metals in cells and tissues. Chem Rev (2009) 2.03

Animal models of cardiovascular diseases. J Biomed Biotechnol (2011) 1.73

Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol (2009) 1.59

Identifying novel genes for atherosclerosis through mouse-human comparative genetics. Am J Hum Genet (2005) 1.46

Differences in health status affect susceptibility and mapping of genetic loci for atherosclerosis (fatty streak) in inbred mice. Arterioscler Thromb Vasc Biol (2012) 1.40

Phenotypic characterization of Bbs4 null mice reveals age-dependent penetrance and variable expressivity. Hum Genet (2006) 1.32

Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Lipids Health Dis (2011) 1.22

In utero arsenic exposure induces early onset of atherosclerosis in ApoE-/- mice. Reprod Toxicol (2007) 1.14

The effects of Tualang honey on female reproductive organs, tibia bone and hormonal profile in ovariectomised rats--animal model for menopause. BMC Complement Altern Med (2010) 1.13

Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice. Pflugers Arch (2008) 1.06

Cardiac and vascular changes in elderly atherosclerotic mice: the influence of gender. Lipids Health Dis (2010) 1.01

Programmable nanoparticle functionalization for in vivo targeting. FASEB J (2012) 1.01

Atherosclerosis as a disease of failed endogenous repair. Front Biosci (2008) 1.00

Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs. PLoS One (2013) 0.97

The fat-fed apolipoprotein E knockout mouse brachiocephalic artery in the study of atherosclerotic plaque rupture. J Biomed Biotechnol (2010) 0.94

Non-specific binding of [18F]FDG to calcifications in atherosclerotic plaques: experimental study of mouse and human arteries. Eur J Nucl Med Mol Imaging (2006) 0.93

Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis. J Biomed Res (2013) 0.93

Dual-energy computed tomography imaging of atherosclerotic plaques in a mouse model using a liposomal-iodine nanoparticle contrast agent. Circ Cardiovasc Imaging (2013) 0.92

11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ mice. PLoS One (2013) 0.89

Effect of diets containing sucrose vs. D-tagatose in hypercholesterolemic mice. Obesity (Silver Spring) (2008) 0.88

Deficiency of a transcriptional regulator, inhibitor of differentiation 3, induces glomerulonephritis in apolipoprotein E-deficient mice: a model linking hyperlipidemia and renal disease. Am J Pathol (2011) 0.86

Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque. Magn Reson Med (2009) 0.86

Nutrigenomic analysis of the protective effects of bilberry anthocyanin-rich extract in apo E-deficient mice. Genes Nutr (2010) 0.86

Mycoplasma pneumoniae and/or Chlamydophila pneumoniae inoculation causing different aggravations in cholesterol-induced atherosclerosis in apoE KO male mice. BMC Microbiol (2009) 0.86

Effects of Aging and Hypercholesterolemia on Oxidative Stress and DNA Damage in Bone Marrow Mononuclear Cells in Apolipoprotein E-deficient Mice. Int J Mol Sci (2013) 0.86

Aging and vascular dysfunction: beneficial melatonin effects. Age (Dordr) (2011) 0.85

Maternal hypercholesterolemia leads to activation of endogenous cholesterol synthesis in the offspring. Am J Obstet Gynecol (2008) 0.85

Differentiated miRNA expression and validation of signaling pathways in apoE gene knockout mice by cross-verification microarray platform. Exp Mol Med (2013) 0.85

Cholesterol and benign prostate disease. Differentiation (2011) 0.85

A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine (2015) 0.82

Hypercholesterolemia promotes early renal dysfunction in apolipoprotein E-deficient mice. Lipids Health Dis (2011) 0.82

Oral P. gingivalis infection alters the vascular reactivity in healthy and spontaneously atherosclerotic mice. Lipids Health Dis (2011) 0.80

Reduction of connexin36 content by ICER-1 contributes to insulin-secreting cells apoptosis induced by oxidized LDL particles. PLoS One (2013) 0.80

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. Drug Des Devel Ther (2015) 0.79

Graded Maximal Exercise Testing to Assess Mouse Cardio-Metabolic Phenotypes. PLoS One (2016) 0.77

Distinct gene signatures in aortic tissue from ApoE-/- mice exposed to pathogens or Western diet. BMC Genomics (2014) 0.77

Targeting activation of specific NF-κB subunits prevents stress-dependent atherothrombotic gene expression. Mol Med (2012) 0.77

Guidelines for assessing mouse endothelial function via ultrasound imaging: a report from the International Society Of Cardiovascular Translational Research. J Cardiovasc Transl Res (2015) 0.77

The role of caveolin-1 and syndecan-4 in the internalization of PEGylated PAMAM dendrimer polyplexes into myoblast and hepatic cells. Eur J Pharm Biopharm (2014) 0.77

Lipotoxic brain microvascular injury is mediated by activating transcription factor 3-dependent inflammatory and oxidative stress pathways. J Lipid Res (2016) 0.76

Endogenous female sex hormones delay the development of renal dysfunction in apolipoprotein E-deficient mice. Lipids Health Dis (2014) 0.76

β3-Adrenoceptor activation attenuates atherosclerotic plaque formation in ApoE(-/-) mice through lowering blood lipids and glucose. Acta Pharmacol Sin (2013) 0.76

The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis. Med Sci Monit (2012) 0.76

High fat diet induces adhesion of platelets to endothelium in two models of dyslipidemia. J Obes (2014) 0.76

Intermittent hypoxia and hypercapnia induce pulmonary artery atherosclerosis and ventricular dysfunction in low density lipoprotein receptor deficient mice. J Appl Physiol (1985) (2013) 0.76

Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway. Exp Ther Med (2017) 0.75

Shengjie Tongyu Granule Inhibits Vascular Remodeling in ApoE-Gene-Knockout Mice. Evid Based Complement Alternat Med (2012) 0.75

Chronic vitamin A-enriched diet feeding regulates hypercholesterolaemia through transcriptional regulation of reverse cholesterol transport pathway genes in obese rat model of WNIN/GR-Ob strain. Indian J Med Res (2016) 0.75

Influence of fatty acids in maternal diet on atherogenesis in offspring of LDL receptor-deficient mice. Int J Clin Exp Med (2012) 0.75

Microscope-based near-infrared stereo-imaging system for quantifying the motion of the murine epicardial coronary arteries in vivo. J Biomed Opt (2013) 0.75

Molecular Imaging of Vulnerable Atherosclerotic Plaques in Animal Models. Int J Mol Sci (2016) 0.75

Apple Peel Supplemented Diet Reduces Parameters of Metabolic Syndrome and Atherogenic Progression in ApoE-/- Mice. Evid Based Complement Alternat Med (2015) 0.75

N-(2-hydroxy) propyl-3-trimethylammonium chitosan chloride: An immune-enhancing adjuvant for hepatitis E virus recombinant polypeptide vaccine in mice. Hum Vaccin Immunother (2017) 0.75

De-alcoholised white and red wines decrease inflammatory markers and NF-κB in atheroma plaques in apoE-deficient mice. Eur J Nutr (2012) 0.75

Evaluation of atherosclerotic lesions in cholesterol-fed mice during treatment with paclitaxel in lipid nanoparticles: a magnetic resonance imaging study. J Biomed Res (2017) 0.75

Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol (2003) 2.89

Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessels of rabbit and from perfused lungs of sensitized guinea pig. Prostaglandins (1975) 2.45

Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol (2006) 2.21

Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature (1978) 2.10

Prostacyclin is a circulating hormone. Nature (1978) 1.60

Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A (1990) 1.54

Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet (1978) 1.53

On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol (1987) 1.43

In vivo method for quantitation for anti-platelet potency of drugs. Naunyn Schmiedebergs Arch Pharmacol (1978) 1.17

Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest (2005) 1.14

The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol (1990) 1.11

Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest (2006) 1.09

Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J Physiol Pharmacol (2007) 1.08

Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol (2005) 1.06

Lipopolysaccharide increases release of a nitric oxide-like factor from endothelial cells. Eur J Pharmacol (1989) 1.04

Prostacyclin (PGI2) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapy. Thromb Res (1978) 1.04

Sodium nitroprusside modulates the fibrinolytic system in the rabbit. Br J Pharmacol (1990) 0.97

Selective inhibition of thromboxane A2 biosynthesis in blood platelets. Nature (1977) 0.95

Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. J Physiol Pharmacol (2006) 0.92

Endothelins release tissue plasminogen activator and prostanoids. Eur J Pharmacol (1990) 0.90

Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrovasodilators. Lancet (1990) 0.89

Fibrinolytic activity of 6-keto-prostaglandin E1. Thromb Haemost (1983) 0.87

The current view on the role of leukotrienes in atherogenesis. J Physiol Pharmacol (2010) 0.87

The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol (2008) 0.86

Kaempferol, but not resveratrol inhibits angiotensin converting enzyme. J Physiol Pharmacol (2008) 0.86

Inhibition of nuclear factor-kappaB attenuates artherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol (2005) 0.85

Superoxide dismutase activity and expression in human venous and arterial bypass graft vessels. J Physiol Pharmacol (2005) 0.84

Respiratory movements alter the generation of prostacyclin and thromboxane A2 in isolated rat lungs: the influence of arachidonic acid-pathway inhibitors on the ratio between pulmonary prostacyclin and thromboxane A2. Prostaglandins (1981) 0.83

Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol (2012) 0.83

Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol (1996) 0.83

Angiotensinogen metabolism in rat aorta: robust formation of proangiotensin-12. J Physiol Pharmacol (2010) 0.82

Effects of nitric oxide and prostacyclin on deformability and aggregability of red blood cells of rats ex vivo and in vitro. J Physiol Pharmacol (1999) 0.81

Production of prostacyclin and prostaglandin E2 in resting and IL-1beta-stimulated A549, HUVEC and hybrid EA.HY 926 cells. J Physiol Pharmacol (2006) 0.81

Interaction between NO donors and iloprost in human vascular smooth muscle, platelets, and leukocytes. J Cardiovasc Pharmacol (1989) 0.81

Third-stage nematode larvae of Contracaecum osculatum from Baltic cod (Gadus morhua) elicit eosinophilic granulomatous reactions when penetrating the stomach mucosa of pigs. Parasitol Res (2015) 0.81

Endothelial secretogogues and deformability of erythrocytes. J Physiol Pharmacol (2002) 0.80

Interaction between stimulators of adenylate and guanylate cyclases in human leukocytes, platelets and arteries. Int J Tissue React (1989) 0.80

Lungs as a generator of prostacyclin--hypothesis on physiological significance. Naunyn Schmiedebergs Arch Pharmacol (1978) 0.80

AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol (2010) 0.80

Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Wien Klin Wochenschr (1996) 0.79

Measurement of angiotensin metabolites in organ bath and cell culture experiments by liquid chromatography - electrospray ionization - mass spectrometry (LC-ESI-MS). J Physiol Pharmacol (2007) 0.79

Prostacyclin therapy in peripheral arterial disease. Thromb Res (1981) 0.79

The role of nitric oxide in regulation of deformability of red blood cells in acute phase of endotoxaemia in rats. J Physiol Pharmacol (1997) 0.79

A possible role of thromboxane A2 (TXA2) and prostacyclin (PGI2) in circulation. Acta Biol Med Ger (1978) 0.79

The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol (2009) 0.79

NADPH oxidase and uncoupled nitric oxide synthase are major sources of reactive oxygen species in oral squamous cell carcinoma. Potential implications for immune regulation in high oxidative stress conditions. J Physiol Pharmacol (2008) 0.79

Release of a prostaglandin E-like substance into mixed venous blood during endotoxin hypotension in cats. Pol J Pharmacol Pharm (1975) 0.78

beta-Pyridylcarbinol (Ronicol) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans. Pharmacol Res Commun (1983) 0.78

BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol (2007) 0.78

Effect of L-arginine on plasminogen-activator inhibitor in hypertensive patients with hypercholesterolemia. N Engl J Med (1993) 0.78

Influence of pre-operative ketoprofen administration (preemptive analgesia) on analgesic requirement and the level of prostaglandins in the early postoperative period. Pol J Pharmacol (2004) 0.78

The current view on biological potency of cationically modified chitosan. J Physiol Pharmacol (2014) 0.78

Angiotensin metabolism in rat stomach wall: prevalence of angiotensin-(1-7) formation. J Physiol Pharmacol (2009) 0.77

Secretory dysfunction of vascular endothelium limits the effect of angiotensin converting enzyme inhibitor quinapril on aggregation of erythrocytes in experimental hypertension. J Physiol Pharmacol (2003) 0.77

Effect of ticlopidine on streptokinase-induced thrombolysis in rats. Wien Klin Wochenschr (1999) 0.77

Inhibition of NOS-2 induction in LPS-stimulated J774.2 cells by 1, 5-isoquinolinediol, an inhibitor of PARP. J Physiol Pharmacol (2006) 0.76

De-aggregatory action of prostacyclin in vivo and its enhancement by theophylline. Prostaglandins (1978) 0.76

On the mechanism of antiaggregatory effect of myricetin. Pol J Pharmacol Pharm (1989) 0.76

The effect of doxycycline on atherogenesis in apoE-knockout mice. J Physiol Pharmacol (2011) 0.76

The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin I metabolism in aorta of apoE-knockout mice. J Physiol Pharmacol (2013) 0.76

The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel--a new thromboxane synthase inhibitor. Wien Klin Wochenschr (1995) 0.76

Endotoxaemia in rats: role of leukocyte sequestration in rapid pulmonary nitric oxide synthase-2 expression. J Physiol Pharmacol (2005) 0.76

Angiotensinogen and angiotensin-converting enzyme mRNA decrease and AT1 receptor mRNA and protein increase in epididymal fat tissue accompany age-induced elevation of adiposity and reductions in expression of GLUT4 and peroxisome proliferator-activated receptor (PPARγ). J Physiol Pharmacol (2011) 0.76

Mass-spectrometric evidence for spontaneous and angiotensin-induced generation of prostacyclin by perfused cat lungs. Prostaglandins (1980) 0.76

[Wound repair]. Postepy Hig Med Dosw (1998) 0.76

Influence of cadmium intoxication on thromboresistance of vascular endothelium in rabbits. J Physiol Pharmacol (1998) 0.76

Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation. Naunyn Schmiedebergs Arch Pharmacol (1984) 0.75

Bioassay of histamine in the presence of prostaglandins. Br J Pharmacol (1976) 0.75

[Prostacyclin, EDRF and arteriosclerosis]. Przegl Lek (1989) 0.75

[Endogenous mechanisms regulating the release of prostacyclin in circulating blood]. Folia Med Cracov (1984) 0.75

Endogenous mechanisms which regulate prostacyclin release. Haemostasis (1979) 0.75

The involvement of adhesion molecules and lipid mediators in the adhesion of human platelets to eosinophils. J Physiol Pharmacol (2005) 0.75

Endogenous mechanisms that regulate prostacyclin release. Adv Prostaglandin Thromboxane Res (1980) 0.75

Prostacyclin and atherosclerosis--experimental and clinical approaches. Adv Exp Med Biol (1988) 0.75

[New method of biologically assaying active substances in mixtures using the cascade technic of washing isolated detector organs]. Folia Med Cracov (1977) 0.75

Formation of lipoxygenase and cyclooxygenase metabolites of arachidonic acid by brain tissue. Biomed Biochim Acta (1984) 0.75

[Role of arachidonic acid metabolites in the mediation of pain]. Postepy Hig Med Dosw (1987) 0.75

Regulatory role of prostaglandins in the vascular system. Mater Med Pol (1976) 0.75

Vasodilatory effect and endothelial integrity in papaverine- and milrinone-treated human radial arteries. J Physiol Pharmacol (2013) 0.75

Effect of glucocorticosteroids on the release of prostaglandin-like substances in anaphylaxis. Agents Actions Suppl (1977) 0.75

Anti-aggregatory prostanoids. Part I. Acta Physiol Pol (1986) 0.75

[In memoriam: Dr. Alfons Mackowski]. Pol Przegl Chir (1973) 0.75

Effect of aspirin on cysteinyl leukotrienes production by eosinophils co-cultured with epithelial cells. J Physiol Pharmacol (2004) 0.75

Novel concept in the mechanism of injury and protection of gastric mucosa: role of renin-angiotensin system and active metabolites of angiotensin. Curr Med Chem (2012) 0.75

Anti-aggregatory prostanoids. Part II. Acta Physiol Pol (1986) 0.75

Almitrine increases plasma fibrinolytic activity through the release of prostacyclin from lungs into circulation. Pharmacol Res Commun (1982) 0.75

Reversal of platelet aggregation by prostacyclin. Pharmacol Res Commun (1978) 0.75

Prostacyclin and thromboxane A2 release in isolated rat lungs. Prostaglandins (1982) 0.75

Eicosanoid balance at early stages of experimental atherosclerosis. Its relationship with plasma fibrinolytic activity and platelet aggregation. Agents Actions Suppl (1986) 0.75

Prostaglandin feedback mechanism limits vasoconstrictor action of norepinephrine in perfused rabbit ear. Experientia (1975) 0.75

Fibrinolytic activity and the effects of beta-pyridylcarbinol (Ronicol) in patients with arteriosclerosis obliterans. Thromb Haemost (1983) 0.75

Stimulatory cholinergic effect on the release of antiaggregatory activity into the circulation of cat and man and its modification by beta-adrenergic antagonists. Eur J Clin Invest (1985) 0.75

Perindoprilat changes ANG (1-9) production in renal arteries isolated from young spontaneously hypertensive rats after ANG I incubation. Physiol Res (2016) 0.75

The influence of hydrocortisone and indomethacin on the release of prostaglandin-like substances during circulatory shock in cats, which was induced by an intravenous administration of rabbit blood. Pharmacol Res Commun (1978) 0.75

Bioassay of prostaglandins in the presence of high concentrations of catecholamines. Pol J Pharmacol Pharm (1976) 0.75

A new endocrine-like function of lungs: generation of prostacyclin. Mater Med Pol (1979) 0.75

[Effect of indomethacin on the cardionecrotropic action of isoprenaline in rats]. Folia Med Cracov (1975) 0.75

[Effect of etmozin on thrombocyte aggregation capacity]. Biull Eksp Biol Med (1982) 0.75

Crossroads of L-arginine/arachidonate metabolism. Thromb Haemost (1997) 0.75

Pharmacology at the Jagiellonian University in Kracow, short review of contribution to global science and cardiovascular research through 400 years of history. J Physiol Pharmacol (2006) 0.75